Next, we developed a prognostic proportional hazard model including the 5 genomic AML classes, as well as the covariates age, gender, ECOG performance status (0–1 vs. 2), log2 WBC count, FLT3-status (TKD, ITDlow, ITDhigh), treatment (midostaurin, placebo), and allogeneic HCT in first CR1 as a time-dependent variable. This evidence concerns the gene FLT3 and acute myeloid leukemia.